Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Myeloid 2Gastrointestinal 2Breast 2Sarcoma 1Plasma cell 1Genitourinary 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 63Leukemia, Myeloid, Acute 60Leukemia, Myelomonocytic, Chronic 25Myeloproliferative Disorders 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Recurrence 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Hematologic Neoplasms 7Leukemia, Biphenotypic, Acute 6Leukemia 5Blastic Plasmacytoid Dendritic Cell Neoplasm 5Primary Myelofibrosis 4Blast Crisis 4Myelodysplastic-Myeloproliferative Diseases 3Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Thrombocytosis 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Prostatic Neoplasms 1Preleukemia 1Polycythemia Vera 1

Interventions

venetoclax 2ruxolitinib 2fludarabine phosphate 2Sirolimus 2Leucovorin 2Immunoglobulin G 2Doxorubicin 2Disulfides 2Cyclophosphamide 2Bortezomib 2Bevacizumab 2Azacitidine 2vactosertib 1trametinib 1temsirolimus 1sargramostim 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1hydrocortisone sodium phosphate 1fludarabine 1enzalutamide 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × venetoclax × Myeloid × Clear all
NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Dana-Farber Cancer Institute

Phase 1 Recruiting
30 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡